Table 3.
Distribution of lipid abnormalities among adults in East Coast, Fujian, China in 2017 and 2-year follow-up.
| Prevalence, * % (95% CI) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1st year (2017) | Follow-up I (2018) | Follow-up II (2019) | |||||||||
| Overall | Male | Female | Overall | Male | Female | Overall | Male | Female | |||
| Sample size | 15,397 | 7,829 | 7,568 | 12,144 | 6,047 | 6,097 | 11,762 | 5,776 | 5,986 | ||
| Lipid | Value | Grading | |||||||||
| Serum Non-HDL-C (mg/dl) | <130 | Optimum | 17.2 (15.3–19.1) | 15.9 (14.1–19.8) | 17.5 (15.9–19.5) | 16.5 (15.1–18.0) | 15.1 (11.4–18.8) | 17.5 (15.9–19.5) | 16.0 (15.1–17.0) | 14.7 (12.5–16.9) | 16.5 (14.9–18.2) |
| 130–159 | Desirable | 28.3 (25.5–31.1) | 25.9 (23.3–29.9) | 31.7 (27.5–33.5) | 23.1 (25.5–31.1) | 22.9 (21.3–24.6) | 24.8 (22.5–27.2) | 21.3 (19.5–23.1) | 21.4 (20.3–22.6) | 24.0 (22.0–26.1) | |
| 160–189 | Borderline | 21.3 (19.6–23.2) | 23.2 (21.1–25.5) | 19.5 (15.7–22.3) | 23.3 (19.6–23.2) | 25.0 (22.6–27.5) | 19.5 (15.7–22.3) | 23.5 (20.6–26.4) | 24.7 (22.6–26.8) | 19.4 (16.7–22.2) | |
| 190–219 | High | 26.2 (23.2–29.2) | 28.2 (24.2–32.2) | 24.2 (20.3–28.1) | 29.2 (32.1–26.7) | 29.6 (33.1–26.8) | 28.8 (32.9–25.7) | 29.0 (27.0–31.1) | 28.6 (33.4–26.1) | 29.3 (33.1–26.1) | |
| ≥220 | Very high | 7.0 (4.1–10.0) | 6.8 (4.3–9.3) | 7.1 (4.1–10.1) | 7.9 (10.1–6.1) | 7.4 (9.3–5.5) | 8.4 (11.6–5.2) | 10.2 (13.1–7.3) | 10.6 (13.1–7.2) | 9.8 (11.7–8.3) | |
| Serum LDL-C (mg/dl) | <100 | Optimum | 20.8 (17.7–23.9) | 20.7 (17.9–23.8) | 20.8 (17.7–23.9) | 19.6 (17.7–21.9) | 19.6 (17.6–21.6) | 19.5 (17.9–21.1) | 18.9 (16.1–20.7) | 18.5 (16.1–20.9) | 19.3 (16.1–20.7) |
| 100–129 | Desirable | 28.6 (26.3–30.9) | 28.8 (25.7–31.7) | 28.5 (26.2–30.8) | 28.5 (26.5–30.5) | 28.6 (26.5–30.7) | 28.4 (26.5–30.5) | 26.5 (23.7–29.3) | 26.4 (23.4–29.4) | 26.6 (23.7–29.3) | |
| 130–159 | Borderline | 24.7 (21.9–27.5) | 25.0 (23.1–27.1) | 24.4 (21.8–27.6) | 24.6 (21.7–27.5) | 24.7 (21.9–27.5) | 24.6 (21.7–27.5) | 23.1 (21.4–24.8) | 23.1 (21.2–24.9) | 23.1 (21.5–24.7) | |
| 160–189 | High | 18.6 (16.4–21.0) | 18.7 (17.2–21.0) | 18.5 (15.1–21.8) | 18.6 (17.6–20.6) | 18.8 (16.8–20.9) | 18.4 (16.0–20.8) | 25.1 (23.3–27.7) | 24.5 (22.3–26.7) | 25.7 (23.9-27.5) | |
| ≥190 | Very high | 7.3 (4.7–10.1) | 6.8 (5.1–8.6) | 7.8 (6.6–9.1) | 8.7 (7.5–9.9) | 8.3 (6.5–9.9) | 9.1 (7.3–11.0) | 6.4 (4.8–8.2) | 7.5 (6.1–9.0) | 5.3 (3.1-7.7) | |
| Serum HDL-C (mg/dl) | ≥60 | High | 16.5 (14.2–18.8) | 16.1 (13.7–18.5) | 16.9 (13.9–19.9) | 16.2 (14.0–18.4) | 15.9 (14.0–17.8) | 17.5 (14.1–20.9) | 15.0 (13.7–16.3) | 14.5 (13.2–15.8) | 15.5 (13.0–18.0) |
| 40–59 | Borderline | 58.2 (56.1–60.3) | 57.8 (55.8–59.8) | 58.6 (55.2–61.0) | 58.1 (55.9–60.3) | 58.0 (55.2–60.8) | 58.2 (55.4–61.0) | 57.3 (55.3–59.3) | 56.9 (55.0–57.8) | 57.7 (56.1–59.3) | |
| <40 | Low | 25.3 (23.7–27.1) | 26.1 (23.7–28.7) | 24.5 (21.9–27.1) | 25.7 (22.9–28.6) | 26.1 (24.3–28.1) | 25.3 (22.0–28.8) | 27.7 (25.4–29.8) | 28.6 (26.4–30.8) | 26.8 (24.8-28.9) | |
| Serum TG (mg/dl) | <150 | Optimum | 40.7 (38.1–43.3) | 40.5 (38.0–43.0) | 40.9 (38.1–43.7) | 40.0 (38.0–42.0) | 39.9 (38.0–42.0) | 40.1 (38.0–42.2) | 39.0 (37.7–40.3) | 38.7 (37.7–40.3) | 39.3 (37.2–41.4) |
| 150–199 | Borderline | 31.4 (29.8–33.0) | 31.4 (29.6–33.2) | 31.3 (29.5–33.1) | 31.0 (29.1–32.9) | 30.9 (29.1–32.9) | 31.1 (29.0–33.2) | 30.9 (29.0–32.8) | 30.8 (29.0–32.8) | 31.0 (28.8–33.2) | |
| 200–499 | High | 21.0 (19.5–23.4) | 22.0 (20.8–23.1) | 19.9 (13.3–22.1) | 22.0 (18.5–25.6) | 22.7 (20.8–24.6) | 21.3 (19.9–23.2) | 22.6 (20.9–24.1) | 23.6 (21.9–25.8) | 21.6 (19.7-24.2) | |
| ≥500 | Very high | 6.9 (5.1–8.8) | 6.1 (4.7–7.8) | 7.9 (5.9–9.9) | 7.0 (5.2–8.9) | 6.5 (5.1–8.0) | 7.5 (5.8–9.3) | 7.5 (5.0–9.1) | 6.9 (5.3–8.6) | 8.1 (6.1-10.1) | |
| Total | From Optimum/low to Borderline* | 67.3 (61.9-72.7) | 66.2 (62.7–69.5) | 68.4 (63.2–73.6) | 65.4 (61.1–69.7) | 64.2 (59.5–68.9) | 66.6 (61.2–72.0) | 63.6 (58.1–68.5) | 62.1 (57.7–66.5) | 65.5 (60.3–70.7) | |
| High and Very high | 32.7 (30.1-34.8) | 33.8 (31.1–35.8) | 31.6 (30.0–33.3) | 34.6 (31.1–37.5) | 35.8 (33.9–37.8) | 33.4 (30.0–36.6) | 36.4 (32.9–39.9) | 37.9 (35.9–39.9) | 34.5 (32.9–36.8) | ||
*Prevalence (%) adjusted for age according to data from Chinese population estimates for the year 2017, 2018, and 2019 according to ATP III—Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; CI, confidence interval; LDL, low-density lipoprotein; HDL, high-density lipoprotein. *p < 0.01 (χ2 test).